Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment Development of Triheptanoin (C7) for Glucose Transporter Type I Deficiency (G1D): A Phase I Maximum Tolerable Dose Trial

NCT03041363 is registered in ClinicalTrials.gov with Juan Pascual as lead sponsor.

NCT NCT03041363
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03041363 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment Development of Triheptanoin (C7) for Glucose Transporter Type I Deficiency (G1D): A Phase I Maximum Tolerable Dose Trial
Lead sponsor
Juan Pascual
Phase
Phase 1
Overall status
Completed
Start date
March 29, 2017
Completion date
December 22, 2017
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy, glucose metabolism disorders, glucose transport defect, glucose transporter protein type 1 deficiency syndrome, glucose transporter type 1 deficiency syndrome, glut1 deficiency syndrome 1, autosomal recessive, glut1ds1